Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply

QR Code

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply

Bibliographic Details
Main Authors:	Chan, Arlene, Buyse, M., Yao, B.
Format:	Journal Article
Published:	The Lancet Publishing Group 2016
Online Access:	http://hdl.handle.net/20.500.11937/36236

Similar Items

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by: Chan, Arlene, et al.
Published: (2016)

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by: Martin, M., et al.
Published: (2017)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
by: Chan, Arlene
Published: (2017)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
by: Au, H., et al.
Published: (2013)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

Author reply
by: Campbell, D., et al.
Published: (2013)

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Re: Authors' reply to Stockwell and colleagues
by: Daube, Mike
Published: (2012)

The role of HER family signalling in breast cancer
by: Kuruppu, Anchala
Published: (2016)

Neuraminidase inhibitors for influenza complications: authors' reply
by: Nguyen-Van-Tam, Jonathan S., et al.
Published: (2014)

Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
by: Aung, Sanda, et al.
Published: (2014)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Biological characterisation of HER2 amplified breast cancer
by: Barros, Fabrício Félix Tabuada
Published: (2013)

Expectant management in pregnancies with ruptured membranes – Authors' reply
by: Morris, Jonathan M., et al.
Published: (2016)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)

Expression of foxp3 tumour infiltrating lymphocytes in her2 positive breast cancer and their association with clinicopathological features
by: Hashim, Sobry
Published: (2023)

Statins for people at low risk of cardiovascular disease: Authors' reply
by: Zomer, E., et al.
Published: (2012)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

Multifunctional Poly(D,L-Lactide-co-Glycolide)/ Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer
by: Ranganathan, Balu, et al.
Published: (2014)

Computational pathology and deciphering the complexity of HER2 expression in breast cancer
by: Atallah, Nehal Mohammed
Published: (2025)

How are the kids? Psychosocial wellbeing and needs of the offspring of breast cancer patients
by: Chih, Hui Jun, et al.
Published: (2019)

Comparison of vaccine efficacy must be based on good clinical data–Authors’ reply
by: Abdul Taib, Nur Asheila, et al.
Published: (2022)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
by: Serra, V., et al.
Published: (2011)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
by: Mackey, J., et al.
Published: (2016)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Translational control of Human Epidermal Growth Factor Receptors, HER2 and HER4 in response to cellular stresses in breast cancer cells
by: Edwards, Arnelle
Published: (2023)

Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib
by: Vogel, C., et al.
Published: (2010)

Bioactivity of black cumin oil on the senescence of HER-2-overexpressing breast cancer cells
by: Faradiba Nur Ahlina,, et al.
Published: (2022)

In reply
by: Ing, C., et al.
Published: (2015)

The child support grant and adolescent risk of HIV infection in South Africa – Authors' reply
by: Cluver, L., et al.
Published: (2014)

Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors α and β in Malaysian breast cancer patients
by: Seow, Heng Fong, et al.
Published: (2010)

Cannot write session to /tmp/vufind_sessions/sess_99a2n1ucbnk77t72de6omq8fuj